Bicyclo Ring System Having The Hetero Ring As One Of The Cyclos (e.g., Chromones, Etc.) Patents (Class 514/456)
Coumarins (including hydrogenated) (Class 514/457)
Tocopherols (e.g., vitamin e, etc.) (Class 514/458)
  • Treatment of glycogen synthase kinase-based disease
    Patent number: 8778986
    Abstract: The bioflavonoid luteolin reduces amyloid-? peptide (A?) generation. Luteolin is also a selective GSK-3 inhibitor that 1) decreases amyloidogenic ?-secretase APP processing, and 2) promotes presenilin-1 (PS1) carboxyl-terminal fragment (CTF) phosphorylation. GSK-3? activity is essential for both PS1 CTF phosphorylation states and PS1-APP interaction. To validate The findings were validated in vivo, using a Tg2576 Alzheimer's Disease model system. Luteolin treatment decreased soluble A? levels, reduced GSK-3 activity, and disrupted PS1-APP association.
    Type: Grant
    Filed: January 25, 2008
    Date of Patent: July 15, 2014
    Assignee: University of South Florida
    Inventors: Jun Tan, Doug Shytle, Kavon Rezai-Zadeh
  • Use of 4-hydroxychalcone derivatives for masking an unpleasant taste
    Patent number: 8778987
    Abstract: The use is described of the 4-hydroxychalcone derivatives of the formula (I) wherein A may represent a single or double bond, R1, R2 and R3, mutually independently, may in each case mean H, OH or (preferably C1-C4) alkoxy, providing that at least one of the residues R1 to R3 means OH, and R4 means H, OH or (preferably C1-C4) alkoxy, and/or (ii) the salts thereof and (iii) mixtures thereof to mask or reduce the unpleasant taste impression of an unpleasant tasting substance, as are corresponding methods and preparations.
    Type: Grant
    Filed: March 12, 2008
    Date of Patent: July 15, 2014
    Assignee: Symrise AG
    Inventors: Jakob Ley, Susanne Paetz, Thomas Riess, Gerhard Krammer
  • Agent for strengthening calcium containing tissue and use thereof
    Patent number: 8778882
    Abstract: The present invention has an object to provide an agent for strengthening calcium-containing tissues, which can be safely applied; and its use: The present invention solves the object by providing an agent for strengthening calcium-containing tissues, which comprises one or more flavones, flavonols, flavanones, flavanonols, anthocyanidins, flavanols, chalcones, and aurones.
    Type: Grant
    Filed: September 15, 2008
    Date of Patent: July 15, 2014
    Assignee: Hayashibara Co., Ltd.
    Inventors: Masaki Miyake, Shimpei Ushio, Kanso Iwaki, Masashi Kurimoto
  • Endoperoxides and methods of photocatalytically synthesizing endoperoxides
    Patent number: 8778988
    Abstract: A method of making an endoperoxide from a diene and oxygen in the presence of a photocatalyst having an excited state lifetime of at least 100 nanoseconds, the endoperoxide being represented by the formula: where R1 is an aryl substituted with at least one group selected from the group consisting of alkoxy, hydroxyl, halogen, carbamate, sulfonamide, silyloxy, amide, and combinations thereof or a substituted or unsubstituted heteroaryl, R2 is hydrogen, alkyl, alkynyl, or aryl, R3 is hydrogen, alkyl, alkynyl, or aryl, R4 is alkynyl or aryl, R5 is hydrogen or a substituent, R6 is hydrogen or a substituent, and A1, A2, and A3 are the same or different atoms and form a divalent group that combines with the two carbon atoms of the endoperoxide ring to form a saturated or unsaturated, substituted or unsubstituted ring system of a size of from five to six atoms.
    Type: Grant
    Filed: May 27, 2011
    Date of Patent: July 15, 2014
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Tehshik P. Yoon, Jonathan D. Parrish, Michael A. Ischay
  • DIAGNOSIS AND TREATMENT METHODS FOR ENTRY OF GASTROINTESTINAL CONTENTS INTO RESPIRATORY TRACT
    Publication number: 20140194504
    Abstract: A method of diagnosing in a subject for the purpose of determining if the subject's gastrointestinal contents has entered the subject's respiratory tract. The qualitative analysis can be also expanded into quantitative analysis, enabling the estimation of either the concentration, or the amount, or both, of the gastrointestinal contents that entered the respiratory tract. The invention also provides methods of treatment based on the identification of aspiration using the methods of the invention.
    Type: Application
    Filed: March 11, 2014
    Publication date: July 10, 2014
    Applicants: The Regents of the University Of California, ARADIGM CORPORATION
    Inventors: Igor Gonda, Homer A. Boushey
  • DIAGNOSIS AND TREATMENT METHODS FOR ENTRY OF GASTROINTESTINAL CONTENTS INTO RESPIRATORY TRACT
    Publication number: 20140194502
    Abstract: A method of diagnosing in a subject for the purpose of determining if the subject's gastrointestinal contents has entered the subject's respiratory tract. The qualitative analysis can be also expanded into quantitative analysis, enabling the estimation of either the concentration, or the amount, or both, of the gastrointestinal contents that entered the respiratory tract. The invention also provides methods of treatment based on the identification of aspiration using the methods of the invention.
    Type: Application
    Filed: March 11, 2014
    Publication date: July 10, 2014
    Applicant: ARADIGM CORPORATION
    Inventor: Igor Gonda
  • COMPOSITION FOR TREATING ATHEROSCLEROSIS AND A PREPARATION METHOD THEREOF
    Publication number: 20140194474
    Abstract: Disclosed are a composition for preventing and treating atherosclerosis which includes chalcone compound. In particular, the chalcone compound bound with 2-hydroxyl in ring A and 4?-methyoxy in ring B has versatile therapeutic potentials on anti-atherosclerosis by acting as PPAR? inducer, p44/42 MAPK inhibitor and cell cycle blocker and does not show toxicity to human aortic smooth muscle cells (HASMCs). In addition, the chalcone compound exhibits synergistic effect with the PPAR? ligand (rosiglitazone) to inhibit cell proliferation and the upregulation of cyclin D1, cyclin D3, interleukin-1? (IL-1?) and interleukin-6 (IL-6) induced by oxidized low density lipoprotein (Ox-LDL).
    Type: Application
    Filed: March 10, 2014
    Publication date: July 10, 2014
    Applicant: Kaohsiung Medical University
    Inventors: Yang-Chang WU, Fang-Rong Chang, Tusty-Jiuan Hsieh, Suh-Hang Juo, An-Shen Lin, Ying-Chi Du
  • HEALTH SUPPLEMENT
    Publication number: 20140193346
    Abstract: Herbal composition and method for the treatment of inflammatory pain associated with tendonitis, bursitis, arthritis, carpal tunnel syndrome, tennis elbow, plantar fasciitis, sports injuries, lower back pain and overexertion, gingivitis and muscle aches, that is compliant with HPUS monographs and/or over-the-counter FDA topical analgesic monograph requirements.
    Type: Application
    Filed: January 7, 2013
    Publication date: July 10, 2014
    Applicant: DRT LABORATORIES LLC
    Inventor: Ronit Arginteanu
  • DIAGNOSIS AND TREATMENT METHODS FOR ENTRY OF GASTROINTESTINAL CONTENTS INTO RESPIRATORY TRACT
    Publication number: 20140194503
    Abstract: A method of diagnosing in a subject for the purpose of determining if the subject's gastrointestinal contents has entered the subject's respiratory tract. The qualitative analysis can be also expanded into quantitative analysis, enabling the estimation of either the concentration, or the amount, or both, of the gastrointestinal contents that entered the respiratory tract. The invention also provides methods of treatment based on the identification of aspiration using the methods of the invention.
    Type: Application
    Filed: March 11, 2014
    Publication date: July 10, 2014
    Applicants: The Regents of the University of California, ARADIGM CORPORATION
    Inventors: Igor Gonda, Homer A. Boushey
  • EPICATECHIN FOR ALLEVIATING SYMPTOMS OF ALLERGY
    Publication number: 20140193534
    Abstract: The present invention relates to epicatechin for use in the prevention or reduction of symptoms of an allergic disorder and/or an allergic reaction. The invention further relates to epicatechin for said use in the form of food, food product, food supplement or pharmaceutical products.
    Type: Application
    Filed: August 23, 2012
    Publication date: July 10, 2014
    Applicant: NESTEC S.A.
    Inventors: Annick Mercenier, Anurag Sigh, Sebastien Holvoet, Fabiola Dionisi, Lucas Actis Goretta
  • HEART FAILURE SUPPRESSING AGENT
    Publication number: 20140194372
    Abstract: Provided are a medicine and a food product that suppress a heart disease such as cardiomegaly and heart failure. Specifically provided is an agent for suppressing a heart disease selected from heart failure, cardiac fibrosis, ventricular wall thickening and cardiomegaly, which comprises luteolin or a derivative thereof as an active ingredient.
    Type: Application
    Filed: July 19, 2012
    Publication date: July 10, 2014
    Applicants: THERAVALUES CORPORATION, THE UNIVERSITY OF TOKYO
    Inventors: Hiroyuki Morita, Ryozo Nagai, Atsuko Nakayama, Tadashi Hashimoto
  • Methods For Treating of SARS
    Publication number: 20140194500
    Abstract: Provided is a method of treating SARS in mammals. The method includes administering a therapeutically effective amount of at least one composition selected from the group consisting of myricetin, scutellarein and a pharmaceutically acceptable salt thereof to a mammal in need of treatment of SARS diseases to suppress the activities of SARS coronavirus helicase.
    Type: Application
    Filed: January 8, 2013
    Publication date: July 10, 2014
    Inventors: Young-Sam Keum, Yong-Joo Jeong, Mi-Sun Yu, Young-Won Chin
  • COMPOSITION FOR EYELASH GROWTH
    Publication number: 20140194501
    Abstract: The present invention relates to a pharmaceutical or cosmetic composition and a method for promoting eyelash growth, wherein nipradilol or pharmaceutically or cosmetically acceptable salts thereof are used as active ingredients. The composition of the invention may comprise prostaglandin F2? analogues.
    Type: Application
    Filed: June 8, 2012
    Publication date: July 10, 2014
    Applicant: SK CHEMICALS CO., LTD.
    Inventors: Sang-hwan Kang, Keun-Ho Ryu, DongChul Shin, Bong-yong Lee
  • Methods of treating hematologic cancers
    Patent number: 8772264
    Abstract: This disclosure relates to the treatment of hematologic cancers, for example, cancers of the blood, by methods that include administration of EGCG and at least one of a purine nucleoside analog and an alkylating agent. In particular, methods of treating chronic lymphocytic leukemia (CLL) and acute lymphocytic leukemia (ALL) are described.
    Type: Grant
    Filed: July 27, 2010
    Date of Patent: July 8, 2014
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Neil E. Kay, Tait D. Shanafelt
  • Formulated tick and insect repellent compositions
    Patent number: 8771718
    Abstract: The present invention pertains to the field of tick- or insect-repellent formulated compositions containing dihydronepetalactone, a nepetalactam, a dihydronepetalactam and/or their respective derivatives, and one or more additives to provide a useful and effective means of delivering the composition in the manner and to the location as desired by the user.
    Type: Grant
    Filed: May 10, 2007
    Date of Patent: July 8, 2014
    Assignee: E I du Pont de Nemours and Company
    Inventors: Mark A. Scialdone, Irwin Palefsky
  • Formulations and uses of retinoic acid receptor selective agonists
    Patent number: 8772273
    Abstract: The invention provides retinoic acid receptor (RAR) selective agonists and formulations thereof for the treatment of disease or for inducing a medically beneficial effect.
    Type: Grant
    Filed: October 4, 2011
    Date of Patent: July 8, 2014
    Assignee: QuRetino Therapeutics, Inc.
    Inventor: Ferenc Makra
  • Methods and Compositions for Reducing Skin Damage
    Publication number: 20140186277
    Abstract: The RhoE GTPase pathway has been identified as a target for screening and treatment methods for the prevention and/or reduction of short- and long-term UVB-induced skin damage, e.g., the prevention and/or reduction of UVB-induced wrinkles. The invention thus features screening and treatment methods for prevention or reduction of UVB-induced skin damage, and related compositions, e.g., cosmetic compositions.
    Type: Application
    Filed: September 5, 2013
    Publication date: July 3, 2014
    Applicants: Shiseido Co., Ltd., The General Hospital Corporation
    Inventors: Sam W. Lee, Lakshmi Raj, Anna I. Mandinova, Haruhi Iwaki, Yuji Katsuta, Jotaro Nakanishi
  • POLYPHENOL ANALOGS TO TREAT ISCHEMIA
    Publication number: 20140186329
    Abstract: The present invention provides methods of use of polyphenol compounds for treating, preventing, mitigating and delaying ischemia or a condition where ischemia occurs. In one embodiment, the method comprises providing a polyphenol analog; and administering the polyphenol analog to a subject to treat ischemia or a condition where ischemia occurs. Various embodiments of the present invention are useful for the treatment of patients having, or at risk for, any of (1) ischemic stroke, (2) hemorrhagic stroke, (3) cardiovascular disease, (4) ischemia related spinal cord injury, (5) ischemia in diabetic patients, or (6) embolic stroke. For example, use of the polyphenol compounds can maintain glutathione levels in the patient.
    Type: Application
    Filed: February 6, 2014
    Publication date: July 3, 2014
    Inventors: Paul A. Lapchak, David R. Schubert, Pamela A. Maher, Chandramouli Chiruta
  • COSMETIC COMPOSITION CONTAINING GREEN TEA COMPONENT
    Publication number: 20140186315
    Abstract: The present invention provides a cosmetic composition containing one or more selected from a group consisting of green tea saponin and green tea polyphenol as active ingredients. The cosmetic composition of the invention is very safe to the skin and can greatly enhance biological mechanisms in the skin, and thus can serve as an anti-aging cosmetic composition.
    Type: Application
    Filed: August 20, 2012
    Publication date: July 3, 2014
    Applicant: AMOREPACIFIC CORPORATION
    Inventors: Hyun Seo Kang, Seung Hyun Kang, Ji Hyun Kim, Ji Seong Kim, Yong Joo Na, Byung Geun Chae, Sang Hoon Han
  • NEUROPROTECTIVE POLYPHENOL ANALOGS
    Publication number: 20140186328
    Abstract: The present invention provides neuroprotective polyphenol compounds, which can be synthetic analogs of fisetin, baicalein or chlorogenic acid, that maintain neuroprotective, anti-inflammatory, glutathione promoting, and/or antioxidant properties. The neuroprotective polyphenol compounds are useful for promoting, enhancing and/or increasing neuron protection, growth and/or regeneration. The polyphenol compounds further find use for increasing and or maintaining intracellular glutathione (GSH) levels. The polyphenol compounds are also useful for treating, preventing, mitigating and/or delaying neurodegenerative conditions, including diabetes, Parkinson's disease, Huntington's disease, Alzheimer's disease, non-Alzheimer's dementias, multiple sclerosis, traumatic brain injury, spinal cord injury or ALS.
    Type: Application
    Filed: February 5, 2014
    Publication date: July 3, 2014
    Applicant: Salk Institute for Biological Studies
    Inventors: David R. Schubert, Pamela A. Maher, Chandramouli Chiruta
  • MOLECULAR ACTIVATORS OF THE WNT/BETA-CATENIN PATHWAY
    Publication number: 20140187510
    Abstract: The present invention is directed toward a method of treating a subject for a condition mediated by aberrant Wnt/?-catenin signaling by selecting a subject with a condition mediated by aberrant Wnt/?-catenin signaling and administering to the selected subject a compound selected from the group consisting of those set forth in Table 1, Table 2, and a pharmaceutically acceptable salt thereof. A method of similarly modulating the Wnt/?-catenin pathway in a subject is also discussed.
    Type: Application
    Filed: July 11, 2013
    Publication date: July 3, 2014
    Applicants: THE GENERAL HOSPITAL CORPORATION, MASSACHUSETTS INSTITUTE OF TECHNOLOGY, UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR CENTER FOR COMMERCIALIZATION
    Inventors: Randall T. Moon, Travis L. Biechele, Nathan D. Camp, Stephen Haggarty, Daniel Fass
  • METHOD OF MANAGING CHEMOTHERAPY INDUCED ALOPECIA OR CACHEXIA OR BOTH
    Publication number: 20140187624
    Abstract: The present disclosure is related to management of chemotherapy induced side effects namely cachexia and alopecia by administering a pharmaceutical composition comprising pentameric type A procyanidin flavonoid, trimeric procyanidin flavonoid and tetrameric procyanidin flavonoid, optionally along with pharmaceutical excipients.
    Type: Application
    Filed: July 17, 2012
    Publication date: July 3, 2014
    Applicant: INDUS BIOTECH PRIVATE LIMITED
    Inventors: Sunil Bhaskaran, Mohan Vishwaraman
  • METHODS FOR INHIBITION OF SHC-1/P66 TO COMBAT AGING-RELATED DISEASES
    Publication number: 20140179774
    Abstract: The present invention relates to methods of treating one or more symptoms of a SHC-1/p66-related disease, inhibiting ROS generation or for the manufacture of a medicament in the above-mentioned treatment.
    Type: Application
    Filed: December 26, 2012
    Publication date: June 26, 2014
    Applicant: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE
    Inventors: Shau-Feng CHANG, Chun-Hsien MA, Kuo-Yi YANG
  • NEUROGENESIS SCREENING METHOD AND USES THEREOF
    Publication number: 20140179775
    Abstract: Provided herein are methods for detecting and/or confirming the neurogenesis effect of EGCG and/or resveratrol utilizing adipose-derived stem cells (ADSCs). Further provided are methods of promoting neurogenesis in ADSCs. Also provided are methods for the use of EGCG and/or resveratrol for the production of a neurologic component that may be incorporated into a nutritional composition for promoting neurogenesis in a pediatric subject.
    Type: Application
    Filed: October 3, 2013
    Publication date: June 26, 2014
    Inventors: Chenzhong Kuang, Yan Xiao, Dirk Hondmann, Eduard Poels, Zeina Jouni
  • COMPOSITIONS AND/OR ARTICLES WITH IMPROVED SOLUBILITY OF A SOLID ACTIVE
    Publication number: 20140178314
    Abstract: Personal care compositions for use in an absorbent article are disclosed comprising an isosorbide diester having the formula: wherein R? and R? are independently selected from a straight or branched C1-30 chain, which may be saturated or unsaturated. The personal care compositions also comprise a solid cosmetic active soluble in the isosorbide diester and a dermatologically acceptable carrier. The personal care composition may be in the form of an emulsion. A personal care composition is also disclosed comprising an isosorbide diester having the formula: wherein R? and R? are independently selected from a straight or branched C1-30 chain which may be saturated or unsaturated and Z1-Z6 are independently selected from hydrogen, hydroxyl, amino, amido, R?, or R?. Methods of making the aforementioned personal care compositions are also disclosed.
    Type: Application
    Filed: December 16, 2013
    Publication date: June 26, 2014
    Applicant: The Procter & Gamble Company
    Inventors: Paul Robert Tanner, Larry Richard Robinson
  • METHODS OF TREATING HEMOGLOBINOPATHIES
    Publication number: 20140179700
    Abstract: Methods of alleviating the symptoms of hemoglobinopathies, including, but not limited to, sickle cell disease, ?-thalassemia, and hemoglobin H disease are provided. In some embodiments, the methods comprise administering an inhibitor selected from an ERK inhibitor, a MEK inhibitor, and a Raf inhibitor. Methods of inhibiting adhesion of sickle red blood cells to endothelial cells are also provided.
    Type: Application
    Filed: April 30, 2012
    Publication date: June 26, 2014
    Applicant: Duke Univeristy
    Inventor: Rahima Zennadi
  • Cannabinoid receptor binding agents, compositions, and methods
    Patent number: 8758826
    Abstract: A composition comprising a cannabinoid receptor binding agent attached to a particle for the treatment of skin conditions. The particle may be a nanoparticle, such as nanocrystalline cellulose. The particle may further be modified with functional moieties. Drug delivery properties may be modified by coating the particles or using vesicles to deliver the cannabinoid receptor binding agent and particle. A substrate may be used to deliver the composition to the skin.
    Type: Grant
    Filed: July 3, 2012
    Date of Patent: June 24, 2014
    Assignee: Wet Inc.
    Inventor: Jonathan Austin Bevier
  • Plasminogen activator inhibitor-1 inhibitors and methods of use thereof to modulate lipid metabolism
    Patent number: 8759327
    Abstract: The invention relates to plasminogen activator-1 (PAI-1) inhibitor compounds and uses thereof in the treatment of any disease or condition associated with elevated PAI-1. The invention includes, but is not limited to, the use of such compounds to modulate lipid metabolism and treat conditions associated with elevated PAI-1, cholesterol, or lipid levels.
    Type: Grant
    Filed: April 16, 2008
    Date of Patent: June 24, 2014
    Assignees: The Regents of the University of Michigan, University of Maryland, Baltimore, Eastern Michigan University
    Inventors: Daniel A. Lawrence, Dudley Strickland, Jacqueline Cale, Enming J. Su, Cory Emal, Mark Warnock
  • Chromene modulators of chemokine receptor activity
    Patent number: 8759390
    Abstract: The present application describes modulators of MCP-1 or CCR-2 of formula (I) or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein W1, W2, W3, Y, Z, R2, R3, R3? and R4, are defined in the specification. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and transplant rejection using modulators of formula (I) are disclosed.
    Type: Grant
    Filed: July 14, 2009
    Date of Patent: June 24, 2014
    Assignee: Bristol-Myers Squibb Company
    Inventor: Douglas G. Batt
  • S-nitrosoglutathione reductase inhibitors
    Patent number: 8759548
    Abstract: The present invention is directed to inhibitors of S-nitrosoglutathione reductase (GSNOR), pharmaceutical compositions comprising such GSNOR inhibitors, and methods of making and using the same.
    Type: Grant
    Filed: February 10, 2011
    Date of Patent: June 24, 2014
    Assignee: N30 Pharmaceuticals, Inc.
    Inventors: Xicheng Sun, Jian Qiu
  • Reduction of Microglia-Mediated Neurotoxicity by Kv1.3 Inhibition
    Publication number: 20140171455
    Abstract: Methods for deterring microglia-mediated neurotoxicity in a human or non-human animal subjects comprising the step of inhibiting or blocking the intermediate-conductance calcium-activated potassium channel Kv1.3 in microglia, such as in subjects how suffer from neurodegenerative diseases (e.g., Alzheimer's Disease) or ischemic/anoxic/hypoxic conditions. The inhibition or blocking of the KCa1.3 channels may be accomplished by administering a substance that inhibits Kv1.3 in microglia. Examples of Kv1.3 inhibiting substances include certain 5-phenoxyalkoxypsoralens, such as (4-Phenoxybutoxy)psoralen (PAP-1) as well as certain 4-phenoxybutoxy-substituted heterocyclic compounds.
    Type: Application
    Filed: June 8, 2012
    Publication date: June 19, 2014
    Applicant: The Regents of the University of California
    Inventors: Heike Wulff, Lee-Way Jin, Izumi Meezawa
  • SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY
    Publication number: 20140170243
    Abstract: Novel substituted chroman derivatives and intermediate compounds, compositions containing same, methods for their preparation and uses thereof as therapeutic agents particularly as anti-cancer and chemotherapeutic selective agents are described.
    Type: Application
    Filed: February 21, 2014
    Publication date: June 19, 2014
    Applicant: MEI Pharma, Inc.
    Inventors: Andrew Heaton, Alan James Husband
  • PRESERVATION OF THE NEUROMUSCULAR JUNCTION (NMJ) AFTER TRAUMATIC NERVE INJURY
    Publication number: 20140170162
    Abstract: The invention relates to treatment and/or prevention of nerve injury. In one embodiment, the present invention provides a method of preserving the neuromuscular junction (NMJ) in an individual by administering a therapeutically effective dosage of a composition comprising an inhibitor of Wnt3a, and an inhibitor of MMP3 to the individual. In another embodiment, the present invention provides a method of stabilizing NMJ after nerve injury by inhibiting the WNT and beta-catenin signaling pathway and preserving agrin.
    Type: Application
    Filed: December 18, 2013
    Publication date: June 19, 2014
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventor: Ranjan Gupta
  • Chromone Inhibitors of S-Nitrosoglutathione Reductase
    Publication number: 20140163092
    Abstract: The present invention is directed to inhibitors of S-nitrosoglutathione reductase (GSNOR), pharmaceutical compositions comprising such GSNOR inhibitors, and methods of making and using the same.
    Type: Application
    Filed: January 30, 2014
    Publication date: June 12, 2014
    Applicant: N30 Pharmaceuticals, Inc.
    Inventors: Xicheng Sun, Jian Qiu, Jan Wasley
  • METHODS AND COMPOSITIONS FOR TREATING HIV-ASSOCIATED DIARRHEA
    Publication number: 20140163096
    Abstract: Provided herein are methods for treating HIV-associated or highly active antiretroviral therapy (HAART)-associated diarrhea in an HIV positive subject by administering a composition comprising crofelemer to the subject wherein the composition has minimal drug-drug interactions with at least one other compound concurrently administered to the subject to treat an HIV infection. Also provided are methods for treating HIV-associated or highly active antiretroviral therapy (HAART)-associated diarrhea in an HIV positive subject by administering a composition comprising crofelemer to the subject, wherein the composition does not significantly inhibit the activity of at least one other compound concurrently administered to the subject to treat an HIV infection.
    Type: Application
    Filed: March 15, 2013
    Publication date: June 12, 2014
    Inventors: Pam Golden, William Forbes, Enoch Bortey
  • CROSSLINKER ENHANCED REPAIR OF CONNECTIVE TISSUES
    Publication number: 20140161844
    Abstract: A protein crosslinker delivery device includes a body and a protein crosslinker held in a synthetic or natural biodegradable polymer. The body, a coating on the body, or an attachment to the body can contain the protein crosslinker holding biodegradable polymer. The release rate of the crosslinker and total amount of crosslinker released can be controlled by varying the concentration of the crosslinker and by varying the composition and structural characteristics of the degradable polymer. Surface eroding, bulk eroding and naturally occurring biodegradable polymers can be used in conjunction with a variety of nontoxic or minimally-toxic protein crosslinking agents. The devices can be used to treat mechanically damaged, deformed, and nutritionally deficient connective or soft tissues such as the knee meniscus, the spinal disc, the cornea, ligaments and tendons, the soft palate, and skin.
    Type: Application
    Filed: February 12, 2014
    Publication date: June 12, 2014
    Applicant: Orthopeutics, L.P.
    Inventors: Pawel Slusarewicz, David A. Puleo, Thomas Paul Hedman, Sharath C. Sundararaj
  • CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY
    Publication number: 20140161908
    Abstract: Novel chroman derivatives and intermediate compounds, compostions containing same, methods for their preparation and uses thereof as therapeutic agents particularly as anti-cancer and chemotheraputic selective agents are described.
    Type: Application
    Filed: May 10, 2013
    Publication date: June 12, 2014
    Applicant: MEI Pharma, Inc.
    Inventors: Andrew HEATON, Alan HUSBAND
  • Lubiprostone crystal, the use and the method for the preparation thereof
    Patent number: 8748482
    Abstract: The present invention relates to a lubiprostone crystal, the method for the preparation thereof, and a pharmaceutical composition or kit comprising the same, as well as the use of said crystal in the preparation of a medicament for the treatment of gastrointestinal tract diseases, especially constipation. The X-ray powder diffraction pattern of said crystal comprises characteristic peaks measured at the following 2? reflection angles: 14.6±0.2°, 17.0±0.2° and 19.6±0.2°. As compared to amorphous lubiprostone, the crystal of the present invention has the advantages of relative high purity, stable properties and easy-for-storage and use.
    Type: Grant
    Filed: May 15, 2008
    Date of Patent: June 10, 2014
    Assignee: Shanghai Techwell Biopharmaceutical Co., Ltd
    Inventors: Zhijun Tang, Zhonghao Zhuo, Yunman Zheng, Bingming He, Huichun Yang, Jushang Zheng
  • Methods for preventing and treating neurodegenerative diseases
    Patent number: 8747924
    Abstract: The present invention provide a method for the prevention and treatment of a neurodegenerative disease including Alzheimer's Disease, Huntington's Disease, and Parkinson's Disease, using a grape seed extract or one or more compounds derived therefrom. In particular, the present invention provides a method to treat a patient diagnosed with, or at the risk of developing, a neurodegenerative disease by administering a pharmaceutical composition comprising a grape seed extract or one or more compounds derived therefrom to the patient in a therapeutic amount to reduce the accumulation, aggregation or deposition of amyloid beta or its oligomers, and/or to reduce the misfolding, accumulation and/or aggregation of tau proteins or other proteins.
    Type: Grant
    Filed: November 9, 2010
    Date of Patent: June 10, 2014
    Assignee: Icahn School of Medicine At Mount Sinai
    Inventors: Giulio Maria Pasinetti, Lap Ho, Jun Wang
  • Method for treating gastrointestinal disorder
    Patent number: 8748481
    Abstract: The present invention relates to a method for the long term treatment of gastrointestinal disorders in a human subject, which comprises administering an effective amount of a halogenated prostaglandin compound and/or its tautomer to the subject. The method induces substantially no electrolyte shifting during the term of the treatment. The compound used in the present invention can improve quality of life in the human subjects with gastrointestinal disorders, are similarly effective in treating male and female subjects, and also effective in a human subject aged even 65 years and older.
    Type: Grant
    Filed: September 1, 2005
    Date of Patent: June 10, 2014
    Assignee: Sucampo AG
    Inventor: Ryuji Ueno
  • BRAF Mutations Conferring Resistance to BRAF Inhibitors
    Publication number: 20140155399
    Abstract: The present invention relates to methods, compositions and kits concerning resistance to treatment with an anti-cancer agent, specifically an inhibitor of BRAF. In particular embodiments, the invention concerns mutations in a BRAF sequence that confer resistance to a BRAF inhibitor. Identification of such mutations in a BRAF sequence allows the identification and design of second-generation BRAF inhibitors. Methods and kits for detecting the presence of a mutant BRAF sequence in a sample are also provided.
    Type: Application
    Filed: December 4, 2013
    Publication date: June 5, 2014
    Applicant: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Levi Garraway, Caroline Emery
  • Inhibition and treatment of prostate cancer metastasis
    Patent number: 8742141
    Abstract: The present invention provides compounds and methods of inhibiting and treating metastatic prostate cancer. The compounds include MEK4 inhibitors. In another aspect the invention provides methods of identifying inhibitors of metastatic prostate cancer by screening for inhibitors of MEK4.
    Type: Grant
    Filed: July 1, 2013
    Date of Patent: June 3, 2014
    Assignee: Northwestern University
    Inventors: Raymond C. Bergan, Karl A. Scheidt
  • NOVEL USE OF FLAVONE-BASED COMPOUND
    Publication number: 20140148504
    Abstract: The present invention relates to a novel use of a flavone-based compound or a Kaempferia parviflora extract comprising the same. More particularly, the present invention relates to a composition for wrinkle improvement, anti-aging and skin elasticity enhancement or a composition for skin moisturization, which comprises a flavone-based compound or a Kaempferia parviflora extract comprising the same as an active ingredient. The composition of the present invention is very effective in inhibiting the activity of Collagenase-1 (MMP-1) and promoting the synthesis of collagen. Therefore, the composition of the present invention is useful for wrinkle improvement, anti-aging, skin elasticity enhancement, and skin moisturization via the inhibition of moisture loss from the skin.
    Type: Application
    Filed: July 19, 2013
    Publication date: May 29, 2014
    Applicant: Industry-Academic Cooperation Foundation, Yonsei University
    Inventors: Jae Kwan Hwang, Jaekyung Kim
  • USE OF ANTIOXIDANTS FOR THE TREATMENT OF COGNITIVE AND BEHAVIOURAL DISORDERS IN INDIVIDUALS WITH FRAGILE X SYNDROME
    Publication number: 20140148439
    Abstract: The invention relates to the use of antioxidants such as, ascorbic acid (Vitamin C), Tocopherol (Vitamin E), vitamin A and polyphenols, for the treatment of cognitive and behavioural disorders in patients with Fragile X syndrome. Specifically, the invention relates to the use of said antioxidants in a pre-determined concentration in a therapeutic doses, in order to obtain the greatest amount of antioxidants possible in all the tissues of the organism, so as to eliminate the excess free radicals produced in the cells and to treat the aforementioned cognitive and behavioural disorders in patients with Fragile X syndrome.
    Type: Application
    Filed: December 16, 2011
    Publication date: May 29, 2014
    Applicants: SERVICIO ANDALUZ DE SALUD, INSTITUTO MEDITERRANEO PARA EL AVANCE DE LA BIOTECNOLOGIA Y LA INVESTIGACION
    Inventors: María Yolanda De Diego Otero, Lucia María Pérez Costillas, Ignacio Del Arco Herrera
  • ANTI-GLYCATION AGENT COMPRISING A GARCINIA KOLA EXTRACT OR FRACTION
    Publication number: 20140142171
    Abstract: An anti-glycation agent includes a Garcinia kola extract or fraction. The compositions including the extract or the fraction are used to inhibit the glycation of proteins, in particular the glycation of skin proteins involved in cutaneous aging. A method for determining the activity of compounds for inhibiting the glycation of cutaneous proteins, in particular for inhibiting the glycation of collagen is also described.
    Type: Application
    Filed: November 19, 2013
    Publication date: May 22, 2014
    Applicants: LABORATOIRE SHIGETA, UNIVERSITE D'ANGERS
    Inventors: Severine DERBRE, Sylvie MOREL, Pascale RICHOMME, Alexis Kaatio TOURE
  • COMPOSITION AND METHOD FOR INFLUENCING ENERGY METABOLISM AND TREATING METABOLIC AND OTHER DISORDERS
    Publication number: 20140142170
    Abstract: A composition and method for influencing energy metabolism and treating metabolic and other disorders is provided. A terpenoid lactone that is a selective activator of SIRT1 is generally in the form of a terpenoid dilactone having a 5-alkeny-loxy-furan-2- one group, such as strigolactone, GR 24, or another strigolactone analog, and is used as a therapeutic agent in a method for influencing energy metabolism and treating metabolic and other disorders. The terpenoid lactone may be administered as an individual agent or combined with a second compound such as a flavonoid, chalconoid, tannin, or nicotinamide inhibition antagonist.
    Type: Application
    Filed: October 27, 2011
    Publication date: May 22, 2014
    Applicant: SIRTUIN VALLEY OY
    Inventors: Markku Laakso, Nagendra Yaluri
  • CROMOLYN DERIVATIVES AND RELATED METHODS OF IMAGING AND TREATMENT
    Publication number: 20140140927
    Abstract: Novel cromolyn analogs useful as imaging agents for detecting atherosclerotic plaques and for treating atherosclerosis and Alzheimer's Disease, and methods of making the cromolyn analogs, are disclosed. The cromolyn analogs have the general formula: wherein X is OH, C1-C6 alkoxyl; Y and Z are independently selected from a C1-C6 alkyl, C1-C6 alkoxyl, halogen, un-substituted or C1-C6 substituted amine, 18F, 19F, or H; and n is 1, 2, or 3; and wherein for structure (I), if n are both 1 and Y and Z are both H and X is OH.
    Type: Application
    Filed: October 22, 2013
    Publication date: May 22, 2014
    Applicant: THE GENERAL HOSPITAL CORPORATION
    Inventors: David R. Elmaleh, Timothy Shoup
  • Medical Food for Cognitive Decline
    Publication number: 20140142172
    Abstract: Nutraceutical formulations that improve cognitive function in adults diagnosed with neurodegenerative disease are provided, which comprise a combination of fisetin and DHA.
    Type: Application
    Filed: May 18, 2012
    Publication date: May 22, 2014
    Applicants: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, DEPARTMENT OF VETERANS AFFAIRS, SALK INSTITUTE FOR BIOLOGICAL STUDIES
    Inventors: Gregory M. Cole, Sally A. Frautschy, David R. Schubert, Pamela A. Maher
  • METHODS OF DESIGNING, PREPARING, AND USING NOVEL PROTONOPHORES
    Publication number: 20140135359
    Abstract: The present invention provides a computer-assisted method of generating a protonophore requiring the use of a computer including a processor. The method includes: designing the protonophore, calculating, using the processor, an estimated protonophoric activity; producing the protonophore if the estimated protonophoric activity corresponds to an U50 of about 20 ?M or less; and determining the uncoupling activity of the protonophore. The present invention also provides novel protonophores that meet the above requirement and their methods of use.
    Type: Application
    Filed: November 12, 2012
    Publication date: May 15, 2014
    Inventor: Louis C. Martineau
  • USE OF EQUOL OF TREATING ANDROGEN MEDIATED DISEASES
    Publication number: 20140135387
    Abstract: Equol (7-hydroxy-3(4?hydroxyphenyl)-chroman), the major metabolite of the phytoestrogen daidzein, specifically binds and blocks the hormonal action of 5?-dihydrotestosterone (DHT) in vitro and in vivo. Equol can bind circulating free DHT and sequester it from the androgen receptor, thus altering growth and physiological hormone responses that are regulated by androgens. These data suggest a novel model to explain equol's biological properties. The significance of equol's ability to specifically bind and sequester DHT from the androgen receptor have important ramifications in health and disease and may indicate a broad and important usage for equol in the treatment and prevention of androgen-mediated pathologies. Thus, equol can specifically bind DHT and prevent DHT's biological actions in physiological and pathophysiological processes.
    Type: Application
    Filed: May 28, 2013
    Publication date: May 15, 2014
    Applicants: Brigham Young University, Children's Hospital Center, Colorado State University Research Foundation
    Inventors: Edwin Douglas Lephart, Trent D. Lund, Kenneth David Reginald Setchell, Robert J. Handa